American Society of Gene and Cell Therapy 2022 (ASGCT)

Back

FORCE™ Platform for Targeted Delivery of Oligonucleotide Therapeutics in Muscle Diseases (presentation)

View

Repeat Dosing With DYNE-101 is Well Tolerated and Leads to a Sustained Reduction of DMPK RNA Expression in Key Muscles for DM1 Pathology in hTfR1/DMSXL Mice and NHPs (presentation)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.